Refractory neuro-Behçet treated by tocilizumab: A case report

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Urbaniak, Piotr ^a   Hasler, Paul ^a   Kretzschmar, Samuel ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Anti interleukin 6; Neuro Beh et; Tocilizumab

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; BACLOFEN; C REACTIVE PROTEIN; COLCHICINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 6; METHYLPREDNISOLONE; PREDNISONE; TAMSULOSIN; TOCILIZUMAB; AUTACOID; IL6 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; ADULT; ARTICLE; ASEPTIC MENINGITIS; BEHCET DISEASE; CASE REPORT; CLINICAL FEATURE; CONDYLOMA ACUMINATUM; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI INFECTION; GENITAL ULCER; HUMAN; LOW BACK PAIN; LYMPHOCYTIC CHORIOMENINGITIS; MALE; NEUROGENIC BLADDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SCROTUM DISORDER; SPINAL CORD ATROPHY; THROMBOPHLEBITIS; URINARY TRACT INFECTION; URINE RETENTION; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CONVALESCENCE; DRUG ANTAGONISM; IMMUNOLOGY; INNERVATION; LEG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT FAILURE; WALKING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LOWER EXTREMITY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RECOVERY OF FUNCTION; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; WALKING;

EID: 84873260003     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. MENDES D, CORRECIA M, BARBEDO M, VAIO T, MOTA M: Behçet's disease a con- temporary review. J Autoimmun 2009; 32: 178-88.
2. KOSEOGLU E, YILDIRIM A, BORLU M: Is headache in Behçet's disease related to silent neurologic involvement? Clin Exp Rheumtol 2011; 29 (Suppl. 67): S32-7.
3. LECCESE P, D'ANGELO S, ANGELA P, CO-NIGLIO G, LIVIERI I: Switching to adalimu- mab is effective in a case of neuro-Behçet's disease refractory to infliximab. Clin Exp Rheumtol 2010; 28 (Suppl. 60): S102.
4. EVEREKLIOGLU C, ER H, TüRKöZ Y, CEK-MEN M: Serum levels of TNF-alfa, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11: 87-93.
5. HAMZAOUI K, HAMZAOUI A, GUEMIRA F et al.: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205.
6. KULABER A, TUGAL-TUTKUN I, SIBEL P et al.: Pro-inflammatory cellular immune response in Behçet's disease. Rheumatol Int 2007; 27: 1113-8.
7. HIROHATA S, OKA H, MIZUSHIMA Y: Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behçet's disease. Cell Immunol 1992; 140: 410-9.
8. HIROHATA S, ISSHIKI K, OGUCHI H et al.: Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet's syndrome. Clin Immunol Immunopathol 1997; 82: 12-7.
9. EVEREKLIOGLU C: Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005; 50: 297.
10. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.